Kornimate/medical-research-clean huggingface dataset:
hernia repair with or without sutures

Conditions: Hernia

Summary: this is a randomized study between two accepted techniques of mesh fixation for laparoscopic hernia repair.

this is a randomized study in which subjects will undergo one or two currently accepted techniques of mesh fixation during laparoscopic ventral hernia repair. subject will undergo mesh fixation with either trans-abdominal sutures and metallic tacks or metallic tacks only. pain will be assessed through week 12, and hernia recurrence will be assessed for 2 years after surgery. subjects will complete pain questionnaires at baseline, each day during hospital stay, and at follow-up visits at 2, 6, and 12 weeks after discharge. quality of life questionnaires will be completed at baseline, at discharge from hospital, and during follow-up visits at 2, 6, and 12 weeks after discharge.

Eligibility criteria:
inclusion criteria: demographics: * age ≥ 18 years old * if female, negative pregnancy test pre-operative findings: * presence of an abdominal hernia associated with previous surgical incision * midline ventral\\incisional hernia demonstrated either on physical examination by investigators or radiologic imaging tests. * ct scan, mri, ultrasound * no evidence of incarceration, strangulation * size of hernia ≥ 4 centimeters or ≤ 20 centimeters (cross-sectional diameter) * multiple hernias cumulative size ≤ 20 centimeters in cross-sectional diameter exclusion criteria: pre-operative history: * severe medical co-morbidities that prevent safe performance of laparoscopic surgery including coronary artery disease, obstructive pulmonary disease, etc. * history of the following: * connective tissue or wound healing disorder (e.g. ehlers-danlos syndrome) * chronic use (defined as greater than 3 months) of narcotic analgesic for pain other than from the hernia that is intended to be repaired * allergy to products used in hernia repair including surgical mesh * any abdominal ventral incisional hernia previously repaired with permanent synthetic mesh placed inside the peritoneal cavity * loss of abdominal domain (i.e. majority of abdominal organs lie outside confines of the abdominal musculature and fascia) * presence of simultaneous intra-abdominal infection * simultaneous presence of a bowel obstruction * history of suspected or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years. * uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, may interfere with study assessments or compliance. intra-operative findings: * simultaneous performance of another surgical procedure during hernia repair other than acts necessary to complete hernia repair (e.g. cutting of abdominal adhesions) * intra-operative identification of full thickness injury to intestine (i.e. enterotomy), liver, bladder, etc.

Keywords: hernia repair
the safety and effectiveness of didanosine plus stavudine plus delavirdine mesylate plus mkc-442 in hiv-infected patients who have not had success with protease inhibitors

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give mkc-442, didanosine (ddi), stavudine (d4t), and delavirdine (dlv) to hiv-positive patients.

patients receive a treatment regimen consisting of didanosine, stavudine, delavirdine, and mkc-442 for 24 weeks. during the study, patients are evaluated for changes from baseline in plasma hiv-1 rna levels and lymphocyte subsets and for development of adverse events and toxicities. samples for population pharmacokinetics are collected from all patients every 4 weeks. patients who experience virologic failure may add hydroxyurea to their treatment regimen or be discontinued from the study. patients who add hydroxyurea to their regimen and subsequently experience virologic failure are discontinued from the study. after week 24, patients with documented virologic response are eligible to continue receiving study treatment until their plasma hiv-1 rna levels return to baseline levels. for patients receiving hydroxyurea beginning at week 24, visits are conducted at weeks 28, 32, 36, and every 12 weeks thereafter. for patients who continue taking didanosine, stavudine, delavirdine, and mkc-442 or who have started hydroxyurea treatment between weeks 12 and 20, follow-up visits are conducted every 12 weeks, or sooner if needed, until the patient permanently discontinues study treatment.

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are hiv-positive. * are at least 18 years old. * have experienced treatment failure on a previous anti-hiv drug combination that contained at least one protease inhibitor. your viral load must be between 5,000 and 50,000 copies/ml after 6 months of continuous treatment with that drug combination. * agree to use a barrier method of birth control, such as condoms, during the study. exclusion criteria you will not be eligible for this study if you: * have a history of certain medical conditions, such as pancreatitis, peripheral neuropathy, seizure disorder, or aids-related cancer (except for kaposi's sarcoma). * are allergic to any of the study drugs. * have ever taken certain anti-hiv medications including non-nucleoside reverse transcriptase inhibitors (nnrtis), ddi, or d4t. * have taken certain other medications including interleukin-2, interferon or a vaccine within 30 days of study entry. * have received radiation therapy or chemotherapy within 30 days of study entry. (local radiation therapy is allowed.) * abuse alcohol or drugs. * are pregnant or breast-feeding.

Keywords: drug therapy, combination reverse transcriptase inhibitors anti-hiv agents
ultrasonographic assessment of carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: mucopolysaccharidosis are lysosomal storage disorders such as hunter, hurler, and sanfilippo syndromes. these patients have a genetic enzyme deficiency that results in the inability to degrade glycosaminoglycans. the glycosaminoglycans accumulate in lysosomes causing cell enlargement and subsequent dysfunction. the accumulation occurs in all tissues including cartilage, joint capsule, and tendons and can lead to carpal tunnel syndrome, trigger digits, and various other orthopaedic manifestations \[van heest, white\]. these children often suffer from severe cognitive impairment and are often unable to communicate pain or numbness. carpal tunnel syndrome is almost always present, but may not become apparent until symptoms are severe and loss of function has occurred. the current gold standard for diagnosis consists of electromyographic (emg) and nerve conduction velocity (ncv) studies under sedation or general anesthetic \[khanna\]. primary objective: the investigators plan to correlate emg findings and median nerve cross-sectional area in children with mucopolysaccharidosis. the investigators hypothesis is that ultrasonography of the carpal tunnel in patients with mucopolysaccharidosis will prove to be an effective, reliable, and safe method to evaluate the median nerve, thus avoiding the need for emg studies and anesthesia. secondary objective: the investigators want to determine the cross-sectional area of the median nerve using ultrasonography in a cohort of healthy children, ages 3-12. the investigators plan to evaluate a cohort of healthy children to determine a normal cross-sectional area of the median nerve.


Eligibility criteria:
inclusion criteria: for the first arm of the study (25 participants): * children with mucopolysaccharidosis presenting to the senior author's clinic with signs or symptoms of carpal tunnel syndrome will be enrolled to receive both an emg and carpal tunnel ultrasound of the upper extremities. for the second arm of the study (100 participants): * healthy children ages 3-12 with no acute upper extremity trauma or history of mucopolysaccharidosis. * 25 additional participants requested in case of inconclusive ultrasound results, patient removal, or other unusable results. exclusion criteria: first arm: * children with mucopolysaccharidosis who have undergone previous treatment for carpal tunnel syndrome. second arm: * acute (\<3month) wrist or hand surgery/injuries. * unable to obtain parental consent or patient assent. * history of mucopolysaccharidosis. * non-english speaking. * cognitive impairment.
cabergoline and coasting to prevent ohss

Conditions: OHSS

Summary: the effectiveness of cabergoline to prevent moderate-severe ohss to coasting.

to randomly compare three study groups under a high risk of developing ohss to one of three arms of management, either coasting for 1 to 3 days or receiving cabergoline for 8 days or coasting for 1 day plus receiving cabergoline for 8 days in icsi patients following the long luteal gnrh agonist protocol.

Eligibility criteria:
inclusion criteria: 1. age \<or= 35, bmi \<or= 30 2. long protocol gnrh agonist cycles 3. estradiol level on day of hcg \>or= 3500 pg/ml 4. retrieving more than 15 oocytes exclusion criteria: 1. male factor 2. uterine factor

Keywords: ohss icsi coasting cabergoline
safety, tolerability, pk and pd of bi 655075 and establishment of bi 655075 dose(s) effective to reverse prolongation of blood coagulation time by dabigatran

Conditions: Hemorrhage

Summary: to investigate safety, tolerability, pk and pd of bi 655075 and to establish the bi 655075 dose(s) effective to reverse prolongation of blood coagulation time by dabigatran


Eligibility criteria:
inclusion criteria: * healthy midage male and female volunteers, age =45 and =64 years, bmi range: =18.5 and =29.9 kg/m2 * healthy elderly male and female volunteers, age =65 and =80 years, bmi range: =18.5 and = 32 kg/m2 * male and female volunteers with mild renal impairment (clcrd 60-90 (ml/min)) in relatively good health, age =45 and =80 years, bmi range: =18.5 and =32 kg/m2 moderate renal impaired (clcrd =30 to \<60 ml/min according cockcroft\&gault formula in relatively good health, age =45 and =80 years, bmi range: =18.5 and =32 kg/m2 exclusion criteria: * any finding of the medical examination (including bp, pr and ecg) deviating from normal and of clinical relevance * any evidence of a clinically relevant concomitant disease (other than mild renal impairment in the respective group) a significant disease is defined as a disease which in the opinion of the investigator * put the volunteer at risk because of participation in the study * may influence the results of the study * may influence the volunteer¿s ability to participate in the study * is not in a stable condition diabetic, hypercholesterolemia or hypertensive subjects can be entered in this trial if the disease is not significant according to these criteria * surgery of the gastrointestinal tract (except appendectomy) * diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * history of relevant orthostatic hypotension, fainting spells or blackouts. * chronic or relevant acute infections * history of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
follow-up of anterior cruciate ligament reconstruction

Conditions: Anterior Cruciate Ligament Rupture

Summary: rupture of anterior cruciate ligament (acl) is a common pathology, but is subject to variability of associated lesions, surgical management and rehabilitation.

in this study, a collect data of patients having undergone an anterior cruciate ligament (acl) reconstruction in order to evaluate the clinical, functional and morphological results of this intervention, in order to improve the management of the patient.

Eligibility criteria:
inclusion criteria: * patients having undergone an anterior cruciate ligament (acl) reconstruction exclusion criteria: * none

Keywords: anterior cruciate ligament reconstruction operative report consultation report isokinetic tests clinical surveys
a safety and efficacy of ccrt with paclitaxel as adjuvant therapy to post-operative advanced endometrial cancer patients

Conditions: Endometrial Cancer

Summary: the purpose of this study is to determine whether post-operative concurrent chemoradiation with paclitaxel is effective and safe in the treatment of high risk postoperative endometrial cancer patients.

postoperative radiotherapy (rt) is the most used adjuvant treatment in high risk endometrial cancer (hrec), and it appears to reduce the incidence of pelvic relapses but doesn't seem to improve survival. paclitaxel (p) has shown in vitro and clinical activity against endometrial cancer, and it is also a potent radiosensitizer by blocking dividing cells in g2/m phase. this study is to evaluate the efficacy and safety of a treatment with concomitant weekly chemotherapy with paclitaxel and rt in high risk advanced endometrial cancer.

Eligibility criteria:
inclusion criteria: * patients undertaken total hysterectomy, bilateral salpingoophorectomy, washing cytology, pelvic and paraaortic lymph node dissection * patients must have the diagnosis of endometrioid type adenocarcinoma with stage iii, iv. * patients must have a gog performance of 0, 1, or 2. * patients must have expected life span over 6 months. exclusion criteria: * patients with peripheral neurotoxicity over grade 2 in ctc criteria. * patients with history of chemotherapy or radiation treatment. * patients with history of arrhythmia,congestive heart failure. * patients with intractable infection.

Keywords: endometrial cancer high risk weekly paclitaxel cuncurrent chemoradiation
comparison of ablls-r and portage guide in the development of receptive language skills autism spectrum disorder.

Conditions: Autism Spectrum Disorders; Non-verbal Learning Disorder

Summary: language is the system someone uses to communicate with another person. this covers the origins and construction of words, their definitions, and the use of language in various contexts. in normally developing children, receptive language skills are typically much more advanced than expressive language skills. however, some studies found that toddlers and kids with asd had a relatively greater impairment in receptive language skills than in expressive language skills. the study will evaluate the ablls-r (assessment of basic language and learning skills test) and portage guidance and compare their effectiveness in developing the receptive language skills in children with autism spectrum disorder (n=12). the study will follow the randomized control trial study design and a purposive sampling technique will be used. data will be collected from a special education centre bases (behaviour and special education services), lahore. children with autism spectrum disorder with mild to moderate severity level will be included in the study. the age range of the children will be from three years to seven years. children with other neurological disorders or any comorbid conditions will be excluded from the study. the consent form will be filled out by parents of children who meet the inclusion criteria. the autism screening tool will apply by the speech and language pathologist. half of the total number of children will receive therapeutic intervention under ablls-r protocol and other will receive interventions under portage guide protocol. the data will be analysed by using spss 22 statistical software. the results of the study of both the groups will be compared and conclusion will be made on the basis of results. receptive language skills are crucial for communication and social interaction. research comparing these assessment tools can contribute to the development of more effective early intervention programs for children with asd. by identifying the most appropriate assessment tool and intervention strategies, these programs can be better designed to support early language development and promote better long-term outcomes. by understanding the strengths and limitations of each assessment tool, professionals can create more individualized treatment plans for children with asd


Eligibility criteria:
inclusion criteria: * children with autism spectrum disorder with mild to moderate severity level will be included in the study. * the age range of the children will be from three years to seven years. exclusion criteria: * children with other neurological disorders or any comorbid conditions will be excluded from the study. * children who are not participated in any kind of other intervention.
complex molecular etiology and cellular landscape of hip osteoarthritis

Conditions: Osteoarthritis, Hip; Rheumatoid Arthritis

Summary: the purpose of this study is to cast light on the highly complex etiology and cellular landscape of hip osteoarthritis by utilising single-cell and spatial omics.

the specific objectives of this project are: 1. using the latest single-cell rna sequencing (scrnaseq) techniques the investigators aim to a) characterize what kind of cell populations are found in different synovial tissues and blood derived samples of oa patients, b) determine how the cell composition differs between arthritic and corresponding non-arthritic tissues, c) map the transcriptional and regulatory landscape of the cells mentioned in a and b focusing on the inflammatory responses, d) determine what are the key molecular pathways activated in oa. 2. to determine if some of the blood-derived immune cell populations or their products could be used as biomarkers for oa. 3. to map the whole transcriptome and proteome of oa and non-arthritic control tissue while keeping the morphological context with spatial omics technologies. 4. further differentiation and identification of oa endotypes utilizing the single-cell and spatial omics data. the project includes a rheumatoid sub-study where the main objective is to compare arthritic tissue and peripheral blood constituents between oa and rheumatoid arthritis patients to explore the differences in the disease mechanisms.

Eligibility criteria:
inclusion criteria for the main (oa) study: cases: adult patients with osteoarthritis in the hip joint and who are going through an elective total hip arthroplasty. controls: non-arthritis adult patients who are going through a trauma-based emergency total hip arthroplasty. ---- inclusion criteria for the rheumatoid sub-study: adult patients with rheumatoid arthritis in the hip joint and who are going through an elective total hip arthroplasty. ---- exclusion criteria: * the body mass index must be below 35 * age \ 74 * the oa patients may not have diabetes, rheumatoid arthritis (ra), or metabolic syndrome. for the rheumatoid sub-study, the exclusion criteria are the same as above except for the ra.

Keywords: single-cell rna sequencing spatial transcriptomics osteoarthritis rheumatoid arthritis spatial proteomics
study of asenapine in elderly subjects with psychosis (a7501021)(p05717)

Conditions: Psychosis

Summary: this study evaluates the safety and tolerability of asenapine in elderly patients with psychosis.


Eligibility criteria:
inclusion criteria: * elderly subjects with psychosis exclusion criteria: * have an uncontrolled, unstable clinically significant medical condition. * have an established diagnosis of dementia
predicting abdominal reoperation

Conditions: Surgery; Abdominal Adhesion

Summary: nationwide retrospective study, to predict the risk of abdominal reoperation.


Eligibility criteria:
inclusion criteria: * all patients undergoing first abdominal or pelvic surgery between june 1st 2009 and june 30th 2011 in scotland. exclusion criteria: * positive history for abdominal surgery
effect of ketoconazole on breathlessness

Conditions: Chronic Obstructive Pulmonary Disease

Summary: beta-endorphins, which are naturally occurring narcotic substances, have been shown to alter the perception of breathlessness. oral ketoconazole, an antifungal antibiotic, increases blood levels of beta-endorphins. the study hypothesis is that oral ketoconazole will reduce ratings of breathlessness induced by resistive breathing loads.

beta-endorphins are naturally occurring narcotic substances (like morphine) that are released by the brain under stressful conditions, such as exercise and when breathing through a resistive load (a tube containing fine wire mesh). in one study of 8 patients with coronary artery disease, ketoconazole, an oral medication used to treat fungal infections, was administered (1,200 mg at 12 midnight and 600 mg at 6 am) and increased blood levels of beta-endorphins five fold. in a recent study performed at dartmouth-hitchcock medical center, we found that ketoconazole increased blood levels of beta-endorphins in all eight patients with chronic obstructive pulmonary disease (copd). mean values increased by 2.5 times at four hours compared with baseline values (p = 0.0078). based on this significant response, we propose to study the effect of ketoconazole on patients' perception of breathlessness induced by resistive breathing loads in a randomized clinical trial. the hypothesis of the study is that ketoconazole will reduce ratings of breathlessness as mediated by the increased levels of beta-endorphins.

Eligibility criteria:
inclusion criteria: * 50 years of age or older; * diagnosis of copd; * current or former smoker of at least 10 pack-years; * post-bronchodilator fev1 greater than or equal to 30% predicted and less than or equal to 80% predicted; post-bronchodilator ratio \< 70% exclusion criteria: * any concomitant disease that might interfere with study procedures; * use of a drug that may cause a possible drug interaction with ketoconazole

Keywords: breathlessness resistive load breathing beta-endorphins